侵袭性垂体腺瘤中EphA2和E-cadherin的表达及临床意义

摘要

Objective To investigate the expression of Eph receptor tyrosine kinase-A2 and E-cadherin in invasive pituitary adenoma and to study its clinical significance.Methods 100 cases of pituitary adenoma specimens were selected.The expression of EphA2 and E-cadherin situation were detected by immunohistochemistry and HE staining detection.And CD34 was used to calculate capillary number of the pituitary adenoma tissue (MVD).The relationship of EphA2, E-cadherin and MVD in invasive pituitary adenoma were analyzed.Results Positive expression rate (88.0%) of EphA2 in invasive group was significantly higher than that in noninvasive group (16.0%), positive expression rate of E-cadherin in invasive group (35.0%) was significantly lower than that in noninvasive group (80.0%).Expression of EphA2 was positively correlated with MVD, and negatively correlated with expression of E-cadherin.Expression of EphA2, E-cadherin and MVD in pituitary adenomas had no obvious correlation with the size of the tumor tissue.Conclusion Expression of EphA2 increased in invasive pituitary adenoma, while expression of E-cadherin decreased.Over expression of EphA2 may be involved in angiogenesis and the development of invasive pituitary adenoma.EphA2 and E-cadherin can be used as a judgment of biological indicators in invasive pituitary adenoma and is likely to become a new diagnosis and treatment target of invasive pituitary adenoma.%目的 研究侵袭性垂体腺瘤中Eph受体酪氨酸激酶A2(EphA2)、E-钙黏蛋白(E-cadherin)的表达及EphA2、E-cadherin与肿瘤血管之间的关系,并分析临床监测EphA2、E-cadherin表达变化的意义.方法 选择2012~2015年期间采集的100例垂体腺瘤标本,50例侵袭组和50例非侵袭组.并应用免疫组化方法及HE染色方法,检测垂体腺瘤标本内的EphA2、E-cadherin表达情况,同时采用CD34方法,计算垂体腺瘤标本内腺瘤组织的微血管密度(MVD),研究分析临床中EphA2、E-cadherin、MVD表达在垂体腺瘤患者侵袭性垂体腺瘤组织内的关系.结果 侵袭组中EphA2阳性表达率达到(88.0%),E-cadherin阳性表达率(35.0%),非侵袭组阳性表达率(16.0%),E-cadherin阳性表达率(80.0%);侵袭组EphA2阳性表达显著高于非侵袭组EphA2阳性表达,侵袭组E-cadherin阳性表达显著低于非侵袭组E-cadherin阳性表达;而EphA2表达与MVD呈正相关.EphA2表达与E-cadherin呈负相关.结论 侵袭性垂体腺瘤中EphA2表达水平增加,E-cadherin表达则并不断降低.进一步研究证实,侵袭性垂体腺瘤中EphA2过表达,与EphA2参与垂体腺瘤血管生成及EphA2有侵袭性有关.因而临床可以将EphA2、E-cadherin作为判断垂体腺瘤侵袭性的生物学指标并有可能成为侵袭性垂体腺瘤诊断和治疗的新靶点.